论文部分内容阅读
目的探讨不同剂量布地奈德混悬液雾化吸入治疗小儿哮喘急性发作的疗效及安全性对比。方法选取2013年10月至2015年10月期间在本院就诊的98例哮喘急性发作的患儿,随机将其分为观察组和对照组,每组49例,对观察组患儿进行常规治疗的基础上给予1.0 mg/次的布地奈德混悬液雾化吸入治疗,对对照组患儿进行常规治疗的基础上给予0.5 mg/次的布地奈德混悬液雾化吸入治疗,对比观察2组患儿的临床疗效及安全性。结果观察组患儿的临床总有效率为98.0%,显著性高于对照组的临床总有效率(71.4%)(χ2=2.678,P=0.039);观察组患儿的喘息、呼吸困难、哮鸣音以及咳嗽等主要临床症状消失时间均显著性短于对照组(P<0.05);观察组组患儿治疗后不良反应总发生率为12.2%,与对照组(8.2%)比较差异无统计学意义(χ2=1.003,P=0.618)。结论大剂量且高频率的应用布地奈德混悬液雾化吸入治疗小儿哮喘急性发作不仅能够提高临床治疗效果,缩短病程,且安全可靠,值得临床进一步推广应用。
Objective To investigate the efficacy and safety of inhalation of budesonide suspension at different doses in the treatment of acute asthma attack in children. Methods A total of 98 children with acute exacerbation of asthma admitted to our hospital from October 2013 to October 2015 were randomly divided into observation group and control group, 49 cases in each group. The children in observation group were treated routinely Based on the given 1.0 mg budesonide suspension atomization inhalation treatment of children in the control group on the basis of routine treatment given 0.5 mg budesonide suspension aerosol inhalation treatment comparison observation The clinical efficacy and safety of 2 groups of children. Results The total effective rate of the observation group was 98.0%, significantly higher than that of the control group (71.4%) (χ2 = 2.678, P = 0.039). The wheezing, dyspnea, asthma (P <0.05). The total incidence of adverse reactions in the observation group was 12.2% after treatment, but there was no statistical difference between the observation group and the control group (8.2%) Significance (χ2 = 1.003, P = 0.618). Conclusion High-dose and high-frequency application of budesonide suspension atomization inhalation for the treatment of acute exacerbation of pediatric asthma can not only improve the clinical curative effect, shorten the course of disease, but also be safe and reliable, so it is worth further clinical application.